Letter: Does irritable bowel syndrome have a greater impact in Western, compared with Asian, patients? Authors' reply

Comment

. 2023 May;57(10):1190-1191.

doi: 10.1111/apt.17497.

Vivek C Goodoory^{1

2}, Elspeth A Guthrie³, Cho Ee Ng⁴, Christopher J Black^{1

2}, Alexander C Ford^{1

2}

Affiliations

¹ Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, UK.
² Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, UK.
³ Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.
⁴ County Durham and Darlington NHS Foundation Trust, Durham, UK.

Comment

Vivek C Goodoory et al. Aliment Pharmacol Ther. 2023 May.

. 2023 May;57(10):1190-1191.

doi: 10.1111/apt.17497.

Vivek C Goodoory^{1

2}, Elspeth A Guthrie³, Cho Ee Ng⁴, Christopher J Black^{1

2}, Alexander C Ford^{1

2}

¹ Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, UK.
² Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, UK.
³ Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.
⁴ County Durham and Darlington NHS Foundation Trust, Durham, UK.

No abstract available

Comment on

Factors associated with lower disease-specific and generic health-related quality of life in Rome IV irritable bowel syndrome.
Goodoory VC, Guthrie EA, Ng CE, Black CJ, Ford AC. Goodoory VC, et al. Aliment Pharmacol Ther. 2023 Feb;57(3):323-334. doi: 10.1111/apt.17356. Epub 2022 Dec 21. Aliment Pharmacol Ther. 2023. PMID: 36544055

1. Goodoory VC, Guthrie EA, Ng CE, Black CJ, Ford AC. Factors associated with lower disease-specific and generic health-related quality of life in Rome IV irritable bowel syndrome. Aliment Pharmacol Ther. 2023;57(3):323-34.
1. Chuah K, Mahadeva S. Letter: does irritable bowel syndrome have a greater impact in Western, compared with Asian, patients? Aliment Pharmacol Ther. 2023;57:1188-9.
1. Goodoory VC, Ng CE, Black CJ, Ford AC. Impact of Rome IV irritable bowel syndrome on work and activities of daily living. Aliment Pharmacol Ther. 2022;56(5):844-56.
1. Goodoory VC, Ng CE, Black CJ, Ford AC. Willingness to accept risk with medication in return for cure of symptoms among patients with Rome IV irritable bowel syndrome. Aliment Pharmacol Ther. 2022;55(10):1311-9.
1. Goodoory VC, Ng CE, Black CJ, Ford AC. Direct healthcare costs of Rome IV or Rome III-defined irritable bowel syndrome in the United Kingdom. Aliment Pharmacol Ther. 2022;56(1):110-20.